Skip to main content

Table 2 Comparison between patient’s characteristics at first presentation to PR center

From: Factors impacting referral of JIA patients to a tertiary level pediatric rheumatology center in North India: a retrospective cohort study

 

Patients diagnosed as JIA at first assessment in PR center (group A, n = 396)

Patients diagnosed as JIA before first assessment in PR center (group B, n = 124)

p value

Age at onset (years)

8.7 [4.2, 11.8]

9.3 [5.4, 12.1]

NS

Age at diagnosis (years)

9.7 [4.9, 12.8]

10.0 [6.1, 12.7]

NS

Median time from onset of symptoms to first assessment in PR center (months)

3.3 [1.4, 10.2]

13.8 [3.8, 34.5]

< 0.001

Median time from onset of symptoms to diagnosis (months)

3.2 [1.4, 10.2]

4.3 [1.5, 15.8]

NS

Median time from diagnosis to first assessment in PR center (months)

0

3.6 [1.2, 19.3]

< 0.001

Musculoskeletal features

AJC

3 [1, 6]

4 [2, 8]

< 0.01

Hip arthritis

94 (23.7)

28 (22.6)

NS

Cervical involvement

21 (5.3)

13 (10.5)

< 0.05

 ESR (mm/h)

51.0 [26.0, 82.0]

42.5 [21.3, 63.8]

< 0.05

Ongoing treatment

NSAIDS

125 (31.6)

60 (48.4)

< 0.001

Corticosteroids (oral, IV, IM)

44 (11.1)

75 (60.5)

< 0.001

Intra articular steroids

1 (0.25)

15 (12.1)

< 0.001

DMARDS

0 (0.0)

102 (82.3)

< 0.001

Biologics

0 (0.0)

9 (7.3)

< 0.001

Alternative medicine

11 (2.8)

2 (1.6)

NS

Non attending to age appropriate school

36 (9.1)

20 (16.1)

< 0.05

Referral (group A) or followed (group B)

Ped

198 (50)

24 (19.4)

< 0.001

Adult rheum

75 (18.9)

82 (66.1)

< 0.001

GP

8 (2)

0 (0)

NS

Ortho

75 (18.9)

18 (14.5)

NS

Self

32 (8.1)

0 (0)

< 0,001

Other

8 (2)

0 (0)

NS

Median distance from the PR center (km)

79.6 [19.8, 422.3]

205.0 [39.0, 688.5]

< 0.001

  1. Data are presented as frequencies (associated percentages) or as median [interquartile range
  2. PR: pediatric rheumatology, JIA: juvenile idiopathic arthritis, AJC: active joint count, ESR:erythrocyte sedimentation rate, NSAIDS: nonsteroidal anti-inflammatory drugs, IV:intravenous, IM: intramuscular, DMARDS: disease-modifying anti-rheumatic drugs